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Background Cachexia affects the majority with advanced cancer. Based on current demographic and clinical factors, it is not
possible to predict who will develop cachexia or not. Such variation may, in part, be due to genotype. It has recently been
proposed to extend the diagnostic criteria for cachexia to include a direct measure of low skeletal muscle index (LSMI) in ad-
dition to weight loss (WL). We aimed to explore our panel of candidate single nucleotide polymorphism (SNPs) for association
with WL +/ computerized tomography-defined LSMI. We also explored whether the transcription in muscle of identified
genes was altered according to such cachexia phenotype
Methods A retrospective cohort study design was used. Analysis explored associations of candidate SNPs with WL (n = 1276)
and WL + LSMI (n = 943). Human muscle transcriptome (n = 134) was analysed using an Agilent platform.
Results Single nucleotide polymorphisms in the following genes showed association with WL alone: GCKR, LEPR, SELP,
ACVR2B, TLR4, FOXO3, IGF1, CPN1, APOE, FOXO1, and GHRL. SNPs in LEPR, ACVR2B, TNF, and ACE were associated with con-
current WL + LSMI. There was concordance between muscle-specific expression for ACVR2B, FOXO1 and 3, LEPR, GCKR, and
TLR4 genes and LSMI and/or WL (P< 0.05).
Conclusions The rs1799964 in the TNF gene and rs4291 in the ACE gene are new associations when the definition of ca-
chexia is based on a combination of WL and LSMI. These findings focus attention on pro-inflammatory cytokines and the
renin–angiotensin system as biomarkers/mediators of muscle wasting in cachexia.
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Introduction
Cachexia affects the majority of patients with advanced can-
cer and is associated with a reduction in treatment tolerance,
response to therapy, quality of life, and duration of survival.1
Cachexia is a complex multifactorial syndrome characterized
by weight loss (WL) and specific losses of muscle and/or
adipose tissue.2 Based on current knowledge, it is not possi-
ble to predict who will develop cancer cachexia and who will
not. Such variation may partly be due to genotype. Knowl-
edge of genotypic variation could contribute to early identifi-
cation of risk and allow institution of prophylaxis.
Using a candidate gene approach, research by our group
identified cancer cachexia with several single nucleotide
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polymorphisms (SNPs); among these, a variant from the SELP
gene (P-selectin3) was investigated for functional significance.
Since then, many new target genes have been reported4–10;
these genes are involved in the key mechanisms thought to
contribute to cancer cachexia, and their transcripts have
been shown to play significant roles in the regulation of path-
ways such as muscle and adipose tissue homeostasis We
have recently published a review of candidate genes and
polymorphisms in cancer cachexia.11,12
Although there is depletion of both adipose tissue and lean
body mass in cancer cachexia, WL per se has long been used
as the diagnostic criterion, and this remains in current classi-
fication systems.13
However, skeletal muscle loss may have the greatest im-
pact on patients’ function and quality of life. It has recently
been possible to quantify muscle mass in cancer patients’ di-
agnostic computerized tomography (CT) scans, and low skel-
etal muscle index (LSMI) so identified is associated with
poor outcome.13–15 One limitation is that due to the absence
of pre-illness scans, it is not possible to document active mus-
cle loss but rather LSMI determined by pre-determined cut-
offs. In the present study, we use LSMI as synonymous with
sarcopenia defined by cut-offs related to excess mortal-
ity.16,17 The combination of LSMI and WL has been suggested
to combine a focus on muscle mass with a dynamic process
of active loss.13 We used >2% WL because this is the minimal
level associated with an increased risk of mortality.17 Such a
combined definition proved superior to its individual compo-
nents in identification of cancer patients with skeletal muscle
fibre atrophy.18
We utilized a candidate gene approach to explore our hy-
pothesis that inter-individual variations in susceptibility to ca-
chexia are partly due to inherited genetic variations (host);
remaining phenotypic variance may be ascribed to the tu-
mour or other comorbidity. One limitation was the lack of
large bio-banks characterized for cachexia phenotypes. We
developed such a bio-bank with our primary objective to
compare our entire panel of candidate SNPs and their associ-
ation with WL with and without LSMI. We also investigated
whether genes demonstrating significant associations had al-
tered transcript expression in muscle from cancer patients
with or without those phenotypes.
Materials and methods
Genotyped cancer patients: new and prior study
cohorts
Subjects were recruited between 2004 and 2012 from the
National Health Service Lothian, UK; Cross Cancer Institute,
Edmonton, Canada; McGill University Health Centre, Mon-
treal, Canada; Palliative Research Centre, Norwegian
University of Science and Technology, Norway; Cantonal
Hospital, St Gallen, Switzerland; and Department of Medical
Oncology, University Hospital of Larissa, Greece (Table 1).
All subjects participated in clinical or research studies on
cancer cachexia at the host institutions under ethically ap-
proved protocols allowing for analysis of patients’ DNA. Re-
cruitment was on presentation to surgical, oncology, or
palliative care clinics. Recruitment was sequential with the
following exclusions: (i) <18 years; (ii) cognitive impair-
ment; (iii) underlying infection; and (v) on corticosteroids.
Overall, 1276 patients were included (Table 1). More than
98% were of European descent. Information on patients in-
cluded date of birth, date of diagnosis, and type and stage
of cancer. Height and weight were measured upon recruit-
ment (at time of diagnosis of cancer). Pre-morbid weight
was recalled and verified where possible from the medical
notes. WL was calculated and expressed as percentage of
pre-morbid body weight lost. The documentation of WL de-
pends on accurate recall. Studies in healthy populations
suggest a strong correlation between recalled and mea-
sured weight.19 CT scans closest to the time of diagnosis
(within 30 days on average) were selected. About 943 pa-
tients were informative for cachexia according to WL and
LSMI. All patients provided written informed consent for
analysis of their DNA.
Table 1 Patient demographics
n=1276














Body mass index (kg/m2)a Range 25±5 (13–59)
Percentage weight lossa 6± 9
Skeletal muscle index cm2/m2ab
M 49±9
F 41±7
Patients recruited from 2004 to 2012 at the NHS Lothian, UK; Cross
Cancer institute, Edmonton, Canada; McGill University Health Cen-
tre, Montreal, Canada; Palliative Research Centre, Norwegian Uni-
versity of Science And Technology, Norway; Cantonal Hospital, St
Gallen, Switzerland; and Department of Medical Oncology, Univer-
sity Hospital of Larissa.
Values are number of patients with percentages in parentheses un-
less indicated otherwise.
aValues are mean± SD. Characteristics were measured at first pre-
sentation to a surgical or oncology clinic.
bSkeletal muscle index calculated as lumbar total muscle cross-sec-
tional area (cm2)/height (m2)
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Skeletal muscle transcriptome study
Patients who contributed to the muscle transcriptomic bio-
bank have been described recently.20 Review of medical
charts and CT images identified WL status and muscularity.
Phenotypes
• WL >5%, >10%, >15%. A range of WL was used to pro-
vide a subgroup analysis to identify associations that
would have been missed with a single cut-off: the interest
is to detect all potential associations in a polygenic model
where the variants are likely to be of lower penetrance yet
conferring finite effects.
• LSMI with any degree of WL (>2%): analysis of CT scans al-
lows classification as LSMI or not. Cut-offs for LSMI were
defined in relation to survival duration of advanced cancer
patients.17
Computerized tomography analysis
Digitally stored CT images completed with a spiral CT were
analysed as described previously. Cross-sectional area for
muscle was normalized for stature (cm2/m2) and a lumbar
skeletal muscle index (SMI) computed.16,21 SMI cut-offs for
LSMI were based on a CT-based study of cancer patients by
Martin et al..17
Candidate gene and single nucleotide
polymorphisms selection
Candidate genes and SNP selections were based on a system-
atic literature review.11,12 Candidate SNPs met the following
criteria: previously published association with cancer ca-
chexia,22–24 statistically significant association with cancer ca-
chexia in our prior study but still requiring validation,3 likely
role in cancer cachexia based on functional or clinical rele-
vance in more than one study,12 significant SNPs identified
in a preliminary study,25 and those SNPs that had been iden-
tified in relation to pro-inflammatory/anti-inflammatory
pathways, neuronal melanocortin signalling pathways, energy
regulation, appetite regulation, muscle, and adipose tissue
catabolic pathways since our prior study.12
Genotyping
Genotyping was performed on the Sequenom iPLEX Gold
platform (San Diego, CA, USA) or TaqMan assay (for
rs4280262) using services from the McGill University and Ge-
nome Quebec Innovation Centre, Montreal, Quebec, Canada.
Polymorphisms selected were validated for assay feasibility
using DNA from healthy Caucasians (n = 92) (Coriell Panel,
Coriell Institute of Medicine, CA, USA).26 Of the 148 SNPs se-
lected initially (21 SNPs from a previous association study and
127 newly selected SNPs for this study), for Sequenom plat-
form, 15 SNPs failed at the multiplex assay design stage,
and 15 SNPs were non polymorphic, leaving 118 SNPs for
genotyping. Assay duplicates for 154 samples genotyped for
all 118 SNPs; 100% concordance for replicates was obtained.
Of the 1452 patient samples, detailed clinical annotations for
the study end points were available for 1276 patients (Table
1). Germline DNA isolated from buffy coat cells from these
1276 individuals were interrogated for the 118 SNPs. SNP call
rates >90% were retained for all subsequent analysis (two
SNPs did not meet this criteria; rs4280262 and rs1544410:
call rates of 80 and 86%, respectively). Three SNPs showed
a minor allele frequency <5%, and these were excluded
(rs1805086; rs2536; and rs16139), leaving 113 SNPs from a
total of 62 genes (Supporting Information Table S1). Devia-
tions from Hardy–Weinberg equilibrium (HWE) were
assessed in the Coriell panel of controls using the χ2 test with
1 degree of freedom; a P-value of <0.001 was considered sig-
nificant deviation from the HWE proportions. None of the
118 SNPs considered for association analysis showed devia-
tions from HWE.
Microarray analysis
Microarray analysis was conducted as previously described.20
The data used in this publication have been deposited in the
US National Centre for Biotechnology Information Gene Ex-
pression Omnibus25 and are accessible through GEO series
accession number GSE41726.
Power calculations
Power calculations used Quanto. For the most prevalent ca-
chexia phenotype (i.e. >5% WL, 50% affected), the present
study has 87% power to detect an odds ratio of 1.5 for SNPs
with a mean allele frequency of >0.05. For the least preva-
lent cachexia phenotype (i.e. >15% WL, 16% affected), the
present study has 35% power to detect an odds ratio of 1.5
for SNPs with a mean allele frequency of >0.05.
Statistical analysis
Gene association study
Statistical analysis was conducted as previously described.3
Briefly, analyses were performed using PLINK (version
1.06).27 Analyses were adjusted for covariates: age at diagno-
sis, sex, pre-diagnosis body mass index, tumour type, and
stage. Patients meeting the criteria for each of the cachexia
phenotypes were compared with patients who had lost
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<5% body weight as control. To account for multiple testing,
permutation testing was performed using the adaptive per-
mutation test in PLINK within each phenotype. Finally, candi-
date genes (and the SNPs in the corresponding gene regions)
were grouped on functional similarity according to gene on-
tology (AmiGO) (Supporting Information Table S2). The set-
based test in PLINK was used to analyse association between
grouped SNPs and cachexia = phenotypes. The latter selects
the best set of SNPs whose mean of these single SNP statis-
tics is significant after permutation, which is particularly
suited to large-scale candidate gene studies.28 The empirical
P-values were obtained by a permutation of 10 000 times of
phenotype labels.
Transcriptomic study
Pearson correlation analysis assessed the relationship
between the phenotypes independently (SMI or WL) with
the expression of transcripts from select candidate genes.
t-test compared how SMI or WL values differed with high
vs. low expression for each of the candidate genes. The high
and low groups were determined by expression intensity
and splitting patients into three equal groups. The extremes
were compared while leaving out middle values. Cases
considered for SMI and WL phenotypes for gene expression
were based on sorting of transcript expression in all samples
and binning based on extremes as described earlier. The
samples used for SNP studies and gene expression studies
are from non-matched cases as these two were independent
studies.
Results
Characteristics of the patient population are presented in
Table 1. Average age was 65 ± 13 years (mean ± SD). The
majority was stage III or IV. Average WL was 6 ± 9%. Of the
patients with CT scans for the assessment of muscularity,
47% had LSMI. There were no significant differences in age,
stage of disease, pre-diagnosis body mass index, and percent-
age WL between patients who had CT scans suitable for the
measurement of muscularity and the entire cohort (Table 1).
Weight loss alone phenotype (n=1276)
Table 2 lists results for SNPs associated with cancer cachexia
in patients classified according to WL alone. Sixteen SNPs
had significant associations with various cachexia pheno-
types based on increasing severity of WL. Two SNPs
(rs1935949 and rs4946935) found within chromosome 6 in
the Forkhead box O3 (FOXO3) gene associated with WL of
increasing severity (>5% and >10%) and one SNP
(rs2297627) found in the Forkhead box O1 (FOXO1) gene
associated with WL> 10%.
Weight loss plus low skeletal muscle index
phenotype (n=943)
Table 3 lists all SNPs associated significantly with cancer ca-
chexia classified according to LSMI +WL >2% in all recruited
patients. The analysis compared those with the LSMI +WL
>2% phenotype against those without in the entire cohort.
rs12409877 is in the leptin receptor (LEPR) located on chro-
mosome 3. rs2268757 is located in the activin receptor
type-2B (ACVR2B) gene on chromosome 3. SNPs in the tu-
mour necrosis factor (TNF) (rs1799964) and ACE (rs4291)
genes also associated with the phenotype.
Combining genes with functional similarity
according to gene ontology
Table 4 lists the phenotypes for candidate gene groups as-
sociated with specific cancer cachexia phenotypes. SNPs in
groups of genes involved in appetite regulation, cell adhe-
sion, cell membrane structure and function, and signal
transduction were associated with the phenotype WL
>10%. Only SNPs in the group of genes involved in cell
Table 2 Genes with variants significantly associated with cancer cachexia








5 GCKR rs1647266 C 0.786 (0.664–0.931) 0.006
5 LEPR rs1137100 G 0.781 (0.647–0.942) 0.012
5 GCKR rs780106 C 0.802 (0.678–0.949) 0.012
5 SELP rs6136 C 0.677 (0.504–0.908) 0.013
5 ACVR2B rs2268757 C 1.219 (1.032–1.440) 0.035
5 TLR4 rs1554973 C 1.237 (1.013–1.510) 0.038
5 FOXO3 rs1935949 T 1.241 (1.033–1.491) 0.039
5 FOXO3 rs4946935 A 1.224 (1.019–1.470) 0.042
10 LEPR rs1137100 G 0.665 (0.524–0.843) 0.001
10 SELP rs6136 C 0.514 (0.345–0.766) 0.001
10 IGF1 rs35767 T 0.681 (0.510–0.910) 0.012
10 FOXO3 rs1935949 T 1.306 (1.047–1.630) 0.013
10 CPN1 rs11597390 A 1.237 (1.007–1.519) 0.027
10 LEPR rs12409877 A 0.793 (0.639–0.984) 0.033
10 FOXO3 rs4946935 A 1.277 (1.023–1.594) 0.035
10 APOE rs157580 G 1.239 (1.005–1.528) 0.047
10 FOXO1 rs2297627 C 0.793 (0.637–0.988) 0.049
15 SELP rs6136 C 0.433 (0.247–0.757) 0.005
15 LEPR rs5010905 C 1.551 (1.138–2.112) 0.007
15 IGF1 rs35767 T 0.626 (0.430–0.912) 0.010
15 LEPR rs1137100 G 0.665 (0.486–0.909) 0.011
15 CPN1 rs11597390 A 1.312 (1.012–1.701) 0.040
15 CPN1 rs1049353 A 0.711 (0.514–0.984) 0.042
15 GHRL rs42451 T 1.344 (1.012–1.785) 0.047
CPN1, Carboxypeptidase N polypeptide 1; FO, Forkhead box; LEPR,
leptin receptor; OR, odds ratio; SELP, P-selectin; SNP, single nucleo-
tide polymorphism.
Weight loss >5%, number affected: 633/1276 (49.6%); weight loss
>10%, number affected: 382/1276 (29.9%); weight loss >15%;
number affected: 199/1276 (15.6%).
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adhesion were significant with increasing WL. SNPs in
groups of genes involved in lipid metabolism, appetite reg-
ulation, signal transduction, and glucocorticoid signalling
were associated with the phenotype LSMI and WL >2%.
No SNPs in groups of genes were found to be significant
with all other phenotypes.
Transcriptomic analysis
Table 5 lists the results from correlation and t-test analysis
between phenotypes and gene transcript level for the
genes that showed significant associations with any of the
cachexia phenotypes. Expression of ACVR2B, FOXO1 and
3, GCKR, LEPR, and TLR4 transcripts was significantly associ-
ated with different levels of SMI or WL (P< 0.05). Specifi-
cally, these were all negatively correlated with
muscularity. FOXO1 and 3 and GCKR were the only genes
significantly correlated with WL; these were correlated neg-
atively with WL.
Discussion
Associations with different cachexia phenotypes
In the present study, four SNPs are associated with WL + LSM
(Table 3). Two of these SNPs are associated with muscle me-
tabolism in two genes (ACVR2B and ACE), one with fat me-
tabolism in one gene (LEPR) and one with cytokine
production in one gene (TNF). It would be attractive to assign
specific functional significance to the genetic signatures iden-
tified. For example, ACVR2B decoy receptors abrogate muscle
loss and prolong survival in several murine models of cancer
cachexia.7 rs1799964 in the TNF gene and rs4291 in the ACE
gene are new associations (c.f. WL alone) when classification
is based on WL + LSMI. These findings focus attention on pro-
inflammatory cytokines and the renin–angiotensin system as
biomarkers/mediators of muscle wasting in cachexia. Replica-
tion of the present findings along with genome-wide scans
and an imputation approach to fine map the loci are needed
in parallel with functional studies (see the following) to re-
solve this issue further.
For the WL phenotype, sixteen candidate SNPs were iden-
tified (Table 2). Seven of these SNPs are associated with mus-
cle metabolism in five genes (IGF1, CPN1, FOXO1, FOXO3, and
ACVR2B), four are associated with adipose tissue metabolism
in two genes (LEPR and APOE), two with the immune re-
sponse in two genes (SELP and TLR4), two with corticosteroid
signalling in one gene (GCKR), and one with appetite regula-
tion in one gene (GHRL). Two polymorphisms (rs1935949
and rs4946935) in the gene encoding for FOXO3 were consis-
tently associated with WL of increasing severity (>5% and
>10%) (Table 2). On the basis that WL is a continuum, the ob-
servation that both SELP and FOXO3 associate with the
highest degrees of WL suggests that these signatures may
be of particular significance. A recent study in a mouse model
of cancer cachexia demonstrated that FOXO-dependent tran-
scription is key in controlling diverse gene networks in skele-
tal muscle during cancer cachexia,29
In keeping with our prior study,3 we confirmed in a larger
validation cohort (Stage 2, n = 545) that patients who carry
the C allele of the rs6136 SNP in the SELP gene are at a re-
duced risk of cachexia defined by WL (>5%, >10%). This
was confirmed recently in chemo-naïve patients with locally
advanced or metastatic pancreatic cancer.30
Gene group analysis
The two dominant mechanisms of WL in cancer are anorexia
/reduced food intake and abnormal metabolism.13 Appetite
regulation was found to associate with the cachexia trait
WL >10% (P = 0.0041). Regarding metabolism, lipid metabo-
lism associated with LSMI and WL >2% (P = 0.0138). Fatty in-
filtration (myosteatosis) has been associated with cancer
Table 3 Genes with variants significantly associated with cancer cachexia
in patients classified according to weight loss >2% and low skeletal mus-
cle index compared with those who do not
Gene SNP Risk allele OR (95%CI) Permutated p
LEPR rs12409877 A 0.674 (0.526–0.865) 0.002
ACVR2B rs2268757 C 1.406 (1.126–1.757) 0.002
TNF rs1799964 C 1.435 (1.093–1.885) 0.010
ACE rs4291 T 1.313 (1.039–1.659) 0.025
LEPR, leptin receptor; OR, odds ratio; SNP, single nucleotide poly-
morphism; TNF, tumour necrosis factor.
WL >2%+ LSMI. Number affected: 214/943 (22.7%).











N/A N/A N/A N/S
Weight loss
>10%
Appetite regulation 8 21 0.004




Signal transduction 51 110 0.038
Weight loss
>15%




Appetite regulation 8 21 0.014




Lipid metabolism 15 38 0.039
LSMI, low skeletal muscle index; N/A, not applicable; N/S, not sig-
nificant; SNP, single nucleotide polymorphism.
aThe genes in each candidate gene group are listed in Supporting
Information Table S2
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cachexia and reduced survival.17,31 The glucocorticoid signal-
ling pathway also associate with LSMI and WL >2%
(P = 0.0337). Glucocorticoids and associated signalling path-
ways accelerate protein degradation in muscle.32
The muscle transcriptome is altered in the presence of can-
cer cachexia.33,34 In the present study, there was concor-
dance between a proportion of the selected genes and
either the level of WL or muscularity (Table 5). FOXO1
and FOXO3 are good examples: SNPs in both genes associ-
ated with the WL phenotype (Table 2) and transcript levels
of both showed a correlation with WL (Table 5). These
transcription factors are not only key in the pro-
inflammatory driven up-regulation of the ubiquitin–
proteasome pathway but also act as negative regulators
of the anabolic Akt-mTOR pathway.8,35
The present SNP analysis was not genome-wide, and
therefore, other variants with possible functional signifi-
cance may have not have been examined. Equally, the true
functional significance of any individual SNP is mostly un-
known. It may be better to consider the genetic associa-
tions identified as genetic signatures or biomarkers
associated with the cachexia syndrome. Interestingly, 17
of the 19 SNPs reported as showing significant associations
are in intronic, 3′, or 5′ Un translated regions (UTRs). The
purpose was to probe into the potential functional impact
of the loci as SNPs in this study are potentially proxy to
the causal variants (not yet captured in the region), which
may also have an influence on gene expression; as such,
the probe position in the expression array and the SNP po-
sition are not the same. Extrapolation to an SNP under be-
ing an expression quantitative trait loci is premature. The
SNP identified may in some cases also affect gene expres-
sion signatures not addressed herein (as in cis-acting and
trans-acting expression quantitative trait loci). The correla-
tion pattern (albeit, low to modest) observed is still encour-
aging because the trends reported here for an SNP loci and
gene expression are within the scope of known cachexia lit-
erature. There is also a growing body of evidence that
microRNAs are involved in cancer cachexia,36 and it may
be that the newly discovered SNPs alter the gene tran-
scripts of these highlighted genes. Animal models may well
be useful to look at the biology of altering the transcripts
from the genes where the SNPs were found.
Equally, for those genes for which no strong relationship
was found between gene expression and patient character-
istics, it is important to consider that these may not be
transcriptionally regulated. For systemic mediators (e.g. cy-
tokines), it may be that circulating concentration is












% weight loss, %/
100d (n=86)c FDd
t-test of SMI values
for patients with high
vs. low probe
expression P-valuee
t-test of % weight
loss/100d values
for patients with high vs.
low probe expression P-valuee
A_23_P109950 ACVR2B 0.94 0.21 0.03 3.9 0.04 0.86
A_24_P231132 ACVR2B 0.24 0.09 3.0 0.03 0.17
A_23_P151426 FOXO1 0.71 0.22 0.23 4.2 0.01 0.04
A_24_P22079 FOXO1 0.39 0.43 3.5 <0.01 <0.01
A_23_P345575 FOXO3 0.97 0.31 0.29 2.9 <0.01 0.01
A_32_P102062 FOXO3 0.33 0.28 3.1 <0.01 0.01
A_23_P119886 GCKR 0.03 0.06 3.8 0.80 0.03
A_23_P161135 LEPR 0.26 0.00 3.5 <0.01 0.31
A_23_P60306 TLR4 0.60 to 0.85 0.18 0.07 2.1 0.02 0.19
A_24_P69538 TLR4 0.10 0.01 2.1 0.03 0.95
A_32_P66881 TLR4 0.19 0.15 2.0 0.04 0.29
ACE, angiotensin converting enzyme; ACVR2B; activin receptor type-2B; CPN1, carboxypeptidase N polypeptide 1; FD, fold difference;
FOX, forkhead box; IGF1, insulin-like growth factor 1; LEPR, leptin receptor; SMI, skeletal muscle index; TNF, tumour necrosis factor.
aThe following gene probes did not show significant Pearson correlation or significance for the t-test analysis: ACE probes
(A_23_P371777, A_23_P38235, A_24_P365129), ACVR2B probe (A_32_P134209), APOE probe (A_23_P164650), CNR1 probes
(A_23_P214208, A_24_P363259), CPN1 probe (A_23_P98147), GHRL probe (A_23_P40956), IGF1 probes (A_23_P13907,
A_24_P304419, A_24_P304423, A_24_P398572), LEPR probe (A_24_P231104), SELP probe (A_23_P137697), TNF probes
(A_23_P376488, A_24_P50759),
bPearson correlation analysis was conducted only for genes with multiple probes.
cPearson correlation analyses were conducted to identify linear relationships between gene probe intensities and SMI or weight loss. Note
that not all 134 patients had both SMI and weight loss information available, and therefore, the number of patients for the SMI and
weight loss correlation analysis were 102 and 86, respectively.
dFold change= average high expressors/average low expressors.
eThe average sample size for the t-test comparing the SMI values for patients with high vs. low probe expression was 35 and 33, respec-
tively. The average sample size for the t-test comparing the % weight loss/100d values for patients with high vs. low probe expression was
30 and 29, respectively. These sample sizes differed slightly from test to test as not all patients had computing tomography scans for SMI
measurements and not all patients had weight loss values in their clinical charts.
Pearson correlation P-value< 0.05.
Bold figures are the ones that are significant.
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important rather than local expression because tissue-
specific expression may be transient, but the activation of
the signal transduction cascade could be the largest prevail-
ing effect.
It is important that the prevalence of LSMI is in excess of
that observed in the normal age-matched population. The
prevalence of LSMI/sarcopenia in age-matched subjects living
in the community varies according to the definition and
methodology used but is reported between 1 and 29%.37
The prevalence of LSMI in this study was ~48%. Thus, the
gene associations with LSMI represent associations with a
level of muscularity at least partly independent of age, sex,
or stature. Clearly, there are other reasons why cancer pa-
tients may lose muscle mass and weight apart from their
tumour-related cachexia, e.g. severe chronic obstructive pul-
monary disease. Such co-morbidities were not graded pro-
spectively in the current study but should be considered for
the characterization of future cohorts.
Conclusions
Candidate gene SNP analysis offers the advantage that it is
hypothesis-driven and the associations are easily explained
owing to compelling biological rationale. However, the limita-
tions are that the role of hitherto unexplored genes and path-
ways that otherwise contribute to the trait under
investigation are missed. Issues surrounding phenotype com-
plexity are addressed in part in this study, and conducting a
genome-wide association study using high density of markers
on the genome would help relate the overlap of
SNPs/pathways to the phenotypes of interest. The consensus
definitions for phenotypes may evolve in an iterative manner
from the cumulative wisdom from candidate SNPs, genome-
wide association study, and the current definitions available
for cachexia. This could potentially lead to the discovery of
new SNPs depending on the phenotype chosen.
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